Powder: -20°C for 3 years | In solvent: -80°C for 2 years
SKLB1028 is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. It shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 51.00 | |
5 mg | In stock | $ 122.00 | |
10 mg | In stock | $ 197.00 | |
25 mg | In stock | $ 397.00 | |
50 mg | In stock | $ 589.00 | |
100 mg | In stock | $ 843.00 | |
500 mg | In stock | $ 1,730.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 146.00 |
Description | SKLB1028 is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. It shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants. |
Synonyms | Ruserontinib |
Molecular Weight | 443.55 |
Formula | C24H29N9 |
CAS No. | 1350544-93-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 50 mg/mL (112.72 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SKLB 1028 1350544-93-2 Angiogenesis Cytoskeletal Signaling JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR FLT Bcr-Abl Ruserontinib inhibitor inhibit